ENSYSCE BIOSCIENCES, INC. AMENDED AND RESTATED 2021 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE ANDStock Option Grant Notice and Award Agreement • March 31st, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Delaware
Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Amended and Restated Omnibus Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase the number of shares of Common Stock (the “Shares”) set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASESettlement Agreement • March 31st, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • California
This SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE (“Agreement”), is made and entered into effective this August 3, 2021 (the “Effective Date”), by and among DelMorgan Group LLC (“DelMorgan”) Globalist Capital, LLC (“Globalist” and, together with DelMorgan, “Advisor”) and D. Lynn Kirkpatrick, Ph.D. (“Kirkpatrick”) and Ensysce Biosciences, Inc. (the “Company”). Collectively, Advisor, Company, and Kirkpatrick are referred to herein individually as a “Party” or collectively, as “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Email Agreement (defined below).
